272 related articles for article (PubMed ID: 22400032)
1. Murine models of B-cell lymphomas: promising tools for designing cancer therapies.
Donnou S; Galand C; Touitou V; Sautès-Fridman C; Fabry Z; Fisson S
Adv Hematol; 2012; 2012():701704. PubMed ID: 22400032
[TBL] [Abstract][Full Text] [Related]
2. Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas.
Lemasson Q; Akil H; Feuillard J; Vincent-Fabert C
Front Immunol; 2021; 12():669964. PubMed ID: 34113345
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.
Pizzi M; Boi M; Bertoni F; Inghirami G
Leukemia; 2016 Sep; 30(9):1805-15. PubMed ID: 27389058
[TBL] [Abstract][Full Text] [Related]
4. Cellular Therapies for the Treatment of Hematological Malignancies; Swine Are an Ideal Preclinical Model.
Duran-Struuck R; Huang CA; Matar AJ
Front Oncol; 2019; 9():418. PubMed ID: 31293961
[TBL] [Abstract][Full Text] [Related]
5. Overview of the Use of Murine Models in Leukemia and Lymphoma Research.
Kohnken R; Porcu P; Mishra A
Front Oncol; 2017; 7():22. PubMed ID: 28265553
[TBL] [Abstract][Full Text] [Related]
6. New targeted therapies for malignant lymphoma based on molecular heterogeneity.
Horn H; Staiger AM; Ott G
Expert Rev Hematol; 2017 Jan; 10(1):39-51. PubMed ID: 27918211
[TBL] [Abstract][Full Text] [Related]
7. A Preclinical Model for the ATLL Lymphoma Subtype With Insights Into the Role of Microenvironment in HTLV-1-Mediated Lymphomagenesis.
Vicario M; Mattiolo A; Montini B; Piano MA; Cavallari I; Amadori A; Chieco-Bianchi L; Calabrò ML
Front Microbiol; 2018; 9():1215. PubMed ID: 29951044
[TBL] [Abstract][Full Text] [Related]
8. Microenvironmental abnormalities induced by viral cooperation: Impact on lymphomagenesis.
De Paoli P; Carbone A
Semin Cancer Biol; 2015 Oct; 34():70-80. PubMed ID: 25837157
[TBL] [Abstract][Full Text] [Related]
9. The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas.
Refaeli Y; Young RM; Turner BC; Duda J; Field KA; Bishop JM
PLoS Biol; 2008 Jun; 6(6):e152. PubMed ID: 18578569
[TBL] [Abstract][Full Text] [Related]
10. A murine model for B-cell lymphomagenesis in immunocompromised hosts: c-myc-rearranged B-cell lines with a premalignant phenotype.
Felsher DW; Denis KA; Weiss D; Ando DT; Braun J
Cancer Res; 1990 Nov; 50(21):7042-9. PubMed ID: 2208171
[TBL] [Abstract][Full Text] [Related]
11. Characterization of posttransplant lymphomas that express T-cell-associated markers: immunophenotypes, molecular genetics, cytogenetics, and heterotransplantation in severe combined immunodeficient mice.
Waller EK; Ziemianska M; Bangs CD; Cleary M; Weissman I; Kamel OW
Blood; 1993 Jul; 82(1):247-61. PubMed ID: 8100721
[TBL] [Abstract][Full Text] [Related]
12. Molecular classification of aggressive lymphomas-past, present, future.
Wienand K; Chapuy B
Hematol Oncol; 2021 Jun; 39 Suppl 1():24-30. PubMed ID: 34105819
[TBL] [Abstract][Full Text] [Related]
13. ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans.
Hathcock KS; Padilla-Nash HM; Camps J; Shin DM; Triner D; Shaffer AL; Maul RW; Steinberg SM; Gearhart PJ; Staudt LM; Morse HC; Ried T; Hodes RJ
Blood; 2015 Nov; 126(20):2291-301. PubMed ID: 26400962
[TBL] [Abstract][Full Text] [Related]
14. Injection of human primary effusion lymphoma cells or associated macrophages into severe combined immunodeficient mice causes murine lymphomas.
Zenger E; Abbey NW; Weinstein MD; Kapp L; Reis J; Gofman I; Millward C; Gascon R; Elbaggari A; Herndier BG; McGrath MS
Cancer Res; 2002 Oct; 62(19):5536-42. PubMed ID: 12359765
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application.
Mulder TA; Wahlin BE; Österborg A; Palma M
Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261914
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies.
Perincheri S
Front Oncol; 2021; 11():719140. PubMed ID: 34956859
[TBL] [Abstract][Full Text] [Related]
17. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
18. The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors.
Menter T; Tzankov A; Dirnhofer S
Hematol Oncol; 2021 Feb; 39(1):3-10. PubMed ID: 33105031
[TBL] [Abstract][Full Text] [Related]
19. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
20. Linking Immunoevasion and Metabolic Reprogramming in B-Cell-Derived Lymphomas.
Böttcher M; Baur R; Stoll A; Mackensen A; Mougiakakos D
Front Oncol; 2020; 10():594782. PubMed ID: 33251150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
